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Osteoporosis is regarded as the most common chronic metabolic bone condition in humans. In osteoporosis, bone
mesenchymal stem cells (MSCs) have reduced cellular function. Regenerative medicine using adipose-derived stem cell
(ADSC) transplantation can promote the growth and strength of new bones, improve bone stability, and reduce the risk of
fractures. Various methods have been attempted to differentiate ADSCs to functioning specialized cells for prospective
clinical application. However, commonly used therapies have resulted in damage to the donor site and morbidity, immune
reactions, carcinogenic generation, and postoperative difficulties. Photobiomodulation (PBM) improves ADSC differentiation
and proliferation along with reducing clinical difficulties such as treatment failures to common drug therapies and late
initiation of treatment. PBM is a noninvasive, nonthermal treatment that encourages cells to produce more energy and to
undergo self-repair by using visible green and red and invisible near-infrared (NIR) radiation. The use of PBM for ADSC
proliferation and differentiation has been widely studied with multiple outcomes observed due to laser fluence and
wavelength dependence. In this article, the potential for differentiating ADSCs into osteoblasts and the various methods
used, including biological induction, chemical induction, and PBM, will be addressed. Likewise, the optimal laser
parameters that could improve the proliferation and differentiation of ADSC, translating into clinical success, will be
commented on.
1. Introduction
Osteoporosis is a painful, chronic bone disease in humans,
and its incidence is increasing globally [1]. Osteoporosis is
characterized by the overall decrease in bone facets which
brings about the fragility of bones and a highly probable risk
of fractures [2]. At present, while therapy is still successful to
some degree, there is a large discrepancy in the care of this
disease. Regenerative medicine is considered a possible solu-
tion by the medical science world. The aim is to heal and treat
diseased, impaired, or age-related tissue complications [3].
Currently, standing at the frontlines of regenerative medicine
is stem cell therapy, due to the ability of stem cells to self-
renew and differentiate into various cell types [4]. Stem cells
have the unique ability of branching into numerous cell
types, one of which is adipose-derived stem cells (ADSCs)
[5]. ADSCs have the ability of differentiating into a special-
ized cell line through the use of various growth factors and
physical factors [6]. PBM is understood to enhance the pro-
liferation and differentiation of cells [7]. However, the
numerous but unestablished methodologies to this technique
must still be developed and pursued for a recognizable differ-
ence in stem cell therapy. This review focused on research
outcomes of successful ADSC differentiation into osteogenic
cell lineages. The selected thirty-one result articles summa-
rized in the tables provided involved the use of chemical
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and biological growth factor inducers, PBM, and their com-
bination for the purposes of cell differentiation. This is to
reveal the potential of this particular regenerative therapy
as a worthwhile in vitro pursuit for successful clinical studies
and produce an enhanced form of treatment for osteoporosis.
2. Literature Review
2.1. Osteoporosis. Osteoporosis is a life-long skeletal disease
[8] that is increasingly becoming a global epidemic [9]. Oste-
oporosis is defined as a decrease in bone mass, a decrease in
bone density, and an overall deterioration of bone [2, 10].
This results in the weakening of bones which raises the inci-
dence of fracture risks [10]. The World Health Organization
(WHO) criteria define osteoporosis as a disease where the
bone mass density (BMD) falls within a 2.5 standard devia-
tion or lower than the average value [11]. The greater part
of fractures tends to happen between
the−2:5 < T − score < −1 range [12]. A discrepancy in bone
resorption and development is the means through which
osteoporosis develops [13] and is caused by a decrease in
bone-forming mature osteoblast populations. This decrease
in osteoblast populations is caused by multiple factors such
as mesenchymal stem cells (MSCs) altering their biology,
osteoblast progenitors that lack proliferation ability, a rise
in apoptosis, and an increase in the build-up of marrow adi-
pocytes [14–16]. As it stands, it is estimated that osteoporosis
affects two hundred million individuals, and approximately
nine million fractures that occur per year are brought on by
osteoporotic disease [17]. Osteoporosis is understood to be
unbiased to a specific gender, race, or age; therefore, it has
the ability to affect a variety of individuals [11]. However, this
disease has shown a tendency of affecting Caucasians, elderly
population groups, and specifically postmenopausal females
[18]. Osteoporosis is problematic as it affects the quality of
life of a patient through financial burden, increasing probable
painful fractures as well as morbidity and mortalities [19].
Osteoporotic treatment currently remains limited as most
treatments, which are drug-based therapies, create severe
side effects such as osteonecrosis of the jaw and atypical fem-
oral fractures [20, 21] and may raise breast cancer, stroke,
and cerebral infarction risks if used for extended periods
[22].
2.2. Bone Marrow Stromal Cells. Bone marrow stromal cells
(BMSCs) comprise of a subset of stem cells known as MSCs,
multipotent stromal cells, or skeletal stem cells, which are
able to differentiate into osteoblasts and take part in an essen-
tial role within the “tissue engineering” of new bone [23].
Current studies have identified BMSCs, when featured in
syngeneic, allogeneic, and xenogeneic situations, to exhibit
immunoregulatory traits [24]. BMSCs are regarded as rejec-
tion tolerant supposed by their secretion of varying immuno-
suppressive factors and minimal MHC molecule expression;
thus, a surge in immune reaction postinjection does not
occur [25]. Despite the minimal MHC molecule expression,
BMSCs are capable of NK cell induced lysis defence due to
numerous mechanisms [26]. A majority of studies suggest
that BMSCs stimulate the adaptive immunity in combination
of production of their specific memory T cells [27] within a
small period of time postinfusion into a host and disappear
after approximately two to four days [24]. In summary,
BMSCs secrete soluble factors that induce regulatory T cell
and anti-inflammatory M2 monocyte/macrophage produc-
tion. In company of these cells, BMSCs restrain helper T cells,
B cells, NK cells, and mast cells’ functions. Skeletal progeni-
tors located within the bone marrow cavity are accountable
for the formation of the 3-dimensional skeletal structure that
provides a hematopoietic niche, due to osteoblasts, chondro-
blasts, adipocytes, and stromal fibroblasts’ differentiation
[28]. MSCs were originally designated over 25 years ago to
describe a class of human and mammalian bone marrow
and periosteum cells that could be isolated and grown in cul-
ture while preserving their in vitro potential to induce a range
of mesodermal phenotypes and tissues [29]. These nonhema-
topoietic cells were first identified by Friedenstein et al. in the
bone marrow, identified as a spindle in shape and displayed
properties of stem cells [30, 31]. Following this discovery,
MSCs were extracted from adipose [32], muscle [33], and
umbilical cord [34] sources. Today, these cells are known to
reside in a majority of tissues like the bone marrow, muscle,
fat tissue, and liver [35]. MSCs are acknowledged as adult
stem cells because of their multipotency and self-renewal
abilities [36]. MSCs are only regarded as such if their appear-
ance is fibroblast-like and are able to differentiate into either
osteogenic, adipogenic, or chondrogenic cell lineages [37].
MSCs even possess a special subset of cells referred to as den-
tal pulp stem cells (DPSCs) which display effortless stimula-
tion in osteogenic differentiation [38], particularly desirable
for dentistry applications. Both bone marrow-derived mes-
enchymal stem cells (BMDMSCs) and ADSCs have been
the commonly studied and characterized cell sources [37].
BMDMSCs are located in the bone marrow and harvested
through a bone marrow aspiration under a local sedation
which yields low cell numbers and has a tendency to differen-
tiate into osteogenic cell type [39]. BMDMSCs function fore-
most as osteogenic progenitors as well as regulate
hematopoietic stem cell (HSC) function through the secre-
tion of trophic factors and maintenance of the HSC niche
[36]. ADSCs are located in adipose tissue and harvested from
minimally invasive lipoaspirates which yield large cell
amounts and are better able to differentiate into a variety of
cell types particularly adipocytes, osteoblasts, and chondro-
cytes making these cells a preferred cell choice [39].
2.3. Osteoblasts. The bone remodelling process consists of
two significant processes, the one being bone resorption
which is enabled by osteoclast cells [40] and the other being
the development of new bone which is the responsibility of
the osteoblast cells [41]. MSCs produce osteoblasts with the
assistance of transcription factors like Osterix, runt-related
transcription factor 2 (Runx2), octamer-binding transcrip-
tion factor 3/4 (Oct4), and L-myc [42]. These significant
functions of osteoblasts are to preserve and renew bone mass,
control the quality of bone, and regulate overall skeletal per-
formance [43–45]. Osteoblasts perform their significant
functions by the creation and release of a variety of proteins
needed for the formation of bone as well as the
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mineralization of the bone matrix [46]. Osteoblast perfor-
mance is affected by a range of influences such as the interac-
tions of the cellular matrix [47], transcriptional and
epigenetic mechanisms [48], inflammatory activities [49],
and cell to cell communication [50]. As displayed in
Figure 1, in the beginning of osteogenesis, MSC populations
will continuously proliferate until committed to osteoblasts
as this then decreases the rate of their proliferation. During
the matrix maturation phase, early osteoblasts will secrete
osteogenic markers like alkaline phosphatase, followed by
the mineralization phase, where late osteoblasts secrete
osteocalcin. At the end of bone formation, these cells will
either develop into bone lining cells and osteocytes or submit
to apoptosis [40].
2.4. Regenerative Medicine. Regenerative medicine is a devel-
oping field of medical science that is aimed at repairing the
functionality and heal tissues or organs that have become dis-
eased, injured, or affected by age-related complications [3].
Regenerative medicine emerged as a strategy to address the
lack of available donor organs and tissues as well as critical
immune rejection responses [51]. To influence the healing
of tissue, restorative cells need to properly influence both
the structure and function of new tissues. This is done using
numerous combinations of both biological and chemical
compounds and newly produced cells [52]; this is the basis
of regenerative medicine (see Figure 2) [53].
The materials used for regenerative medicine are a signif-
icant aspect as they influence structure and function of the
new tissue, offer growth factors, and control the behaviour
of cells by imitating the extracellular matrix [54]. Recently
approved Food and Drug Administration (FDA) regenera-
tive medicine products have either improved or have
remained similar to previous products [55]. This promotes
both healing and regeneration; however, there still remains
a gap in the treatment of disease [56]. Currently, stem cell
therapy is taking the lead in the field of regenerative medicine
because of SCs’ remarkable ability to differentiate into multi-
ple cell types and to unlimitedly self-renew [3].
2.5. Biomaterials/Scaffolds in Regenerative Therapy. Tissue
engineering is an advancing tool for the regeneration of bone;
the blend of cells, scaffolds, and biofactors often leads to a suc-
cessful outcome. The scaffold is a bone tissue engineering
(BTE) tool intended to trounce autografting and allografting
shortcomings [57]; this is a 3D matrix designed for cells with
an osteogenic affinity to attach and proliferate on the scaffold
surface [58]. Two significant characteristics for a bone scaffold
are to be (i) osteoconductive, the inner relocation of mesen-
chymal cells, osteoblasts, osteoclasts, and additional vascula-
ture is to be offered by the scaffold, and (ii) osteoinductive,
the stimulation of cells of different cell lineages to be differen-
tiated into an osteogenic cell lineage [59]. Adult stem cells,











Figure 1: Osteogenic lineage. The process of osteogenic differentiation of MSCs.
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used for BTE as the use of these cells entails no ethical conflict
nor presents as a risk for immune rejection [60]. Scaffolds have
been manufactured from a diverse assortment of materials
such as bioceramics, biopolymers, metals, and composites
[57]. These materials vary in factors like porosity architecture,
mechanical ability, cell bondage, biocompatibility, cell prolif-
eration, osteogenic differentiation ability, and mineralization,
all of which influences the scaffold osteoconductivity and
osteoinduction [57]. Additional studies established that osteo-
genesis is further enhanced by the combination of scaffolds
and osteogenic growth factors such as fibroblast growth factor
(FGF), insulin-like growth factor (IGF), epidermal growth fac-
tor (EPG), and bone morphogenic protein (BMP) which
encourage bone manipulability [59].
2.6. Stem Cell Regenerative Therapy. Stem cells are deemed as
a significantly unique tool for regenerative medicine because
of their self-renewal and multidifferential characteristics [4].
The ability of cells to abundantly divide while preserving
their undifferentiated state is called self-renewal [61]. This
ensures that stem cells are increased during development;
during adulthood, the cell numbers remain constant and
posttrauma, these cell numbers are brought back to the nor-
mal amount [61, 62]. Stem cells do not self-renew to a large
extent when under physiological states, but when cell injury
calls for regeneration, then stem cell potentials alter depend-
ing on the environment of these physiological changes [62].
The potential of a stem cell to differentiate into various types
of cells is termed as potency [61]. The tissue from which stem
cells are extracted will determine their potency because this
changes the differentiation potential [4]. Stem cells are
grouped according to their differentiation potentials as toti-
potent stem cells that form when a sperm fertilizes an oocyte
to produce a zygote, possessing the ability to differentiate into
embryonic and extraembryonic cell types [63]; pluripotent
stem cells differentiate into the three germ layers: the endo-
derm, the mesoderm, and the ectoderm; examples of these
cells are embryonic stem cells (ESCs) and induced pluripo-
tent stem cells (iPSCs) [64]; multipotent stem cells produce
various specialized cells of a particular lineage [65], and uni-
potent cells can only differentiate into one cell type but are
able to self-renew [61]. Stem cells are divided into the follow-
ing types: ESCs, iPSCs, tissue-specific progenitor stem cells
(TSPSCs), umbilical cord stem cells (UCSCs), and MSCs
[66]. ESCs yield large cell amounts through indefinite divi-
sion and differentiate into multiple types of cells [63, 67].
Despite these cells being an ideal regenerative cell type, the
use of these cells come with immense ethical concerns
because their isolation requires the destruction of embryos
during their blastocyst-stage [68]. iPSCs are appealing cells
because they are made from the cells of the patient which
overcomes ethical challenges as well as cell transplant rejec-
tions [69, 70]. However, the differences between ESCs and
iPSCs remain unclear as differences in gene expression,
DNA methylation, and donor cell epigenetic memories are










Figure 2: Regenerative medicine. The isolation of stem cells from the host through biopsy, which are encouraged to proliferate and
differentiate using various growth factors and physical mechanisms. After differentiation, cells are transplanted back into the host.
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TSPSCs are not a preferred cell source because their cell pop-
ulation amount to the total population of cells is insufficient,
therefore, rendering them unsatisfactory for harvesting [71].
UCSCs originate from the umbilical cord, which is rich in
HSCs and MSCs, and make an ideal cell source because they
are obtained noninvasively and unlike ESCs; their use has
minimal ethical conflicts [72]. MSCs are multilineage cells
primarily located in the bone marrow [73, 74] highly capable
of self-renewal, differentiation, and proliferation [36]. MSCs
have the ability to differentiate into either osteogenic, adipo-
genic, or chondrogenic cell lineages, as well as differentiate
into tenocytes, smooth muscle cells, and stromal cells [37].
MSCs further derive into two cell types. The first cell type
is BMDMSCs located in the bone marrow and functions as
osteogenic progenitors and regulators of the HSC niche
[36]. However, their extraction process is extremely invasive
and their proliferation and differentiation abilities are weaker
in comparison to other cell types which makes them unlikely
for selection as a cell source [75]. The second type is ADSCs;
these cells are easily isolated from adipose tissue via a harm-
less lipoaspirate [53, 76] and provide an abundance of cells
able to self-renew. ADSCs are able to differentiate into multi-
ple cell types such as adipocytes, osteoblasts, chondrocytes,
and smooth muscle cells [39].
2.7. Adipose-Derived Stem Cells. ADSCs prove to be a prefer-
able cell source because of two significant qualities: these cells
are easily sourced from adipose tissues preferably located at
the hip and abdomen in abundant amounts [39, 77] and have
no ethical concerns like those of ESCs because ADSCs are iso-
lated from autologous fat [78]. Other advantageous qualities
include antiapoptotic, immunomodulatory, anti-inflamma-
tory, and antiscarring [79]. ADSCs are harvested in one of
three ways: Coleman’s technique [80], liposuction [81], and
excision [80], all of which are less invasive than that of harvest-
ing ESCs. The differentiation potentials of ADSCs do not
change depending on the method used [39] although, as with
any invasive procedure, there lie associated risks such as bleed-
ing, infection, necrosis, and injuries to nerves [36]. In compar-
ison to BMDMSCs, ADSCs are more useful for the making of
collagen than osteogenesis. Nonetheless, ADSCs are consistent
for extended periods of time in culture, both morphologically
and genetically, and as a result are better able to proliferate
[82] and yield abundant amounts of cells during harvesting.
Thus, ADSCs are selected as the preferable cell source [36].
Unfortunately, there is a lack of consensus regarding whether
or not the age of the patient influences the ADSC properties;
some studies state that both the quality and proliferation of
the cells have no association with age [83] whereas others state
that patients younger in age display increased osteogenic and
angiogenic abilities and that older patients display lower dif-
ferentiation and proliferation abilities [39].
2.8. Differentiation of ADSCs into Osteoblasts. To achieve suc-
cessful differentiation of osteogenic lineages from ADMSCs
in vitro, these cells need to be cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM) [84] with a combination of growth
factors like ascorbic acid, β-glycerol phosphate, dexametha-
sone, and 1,25 vitamin D3 [85]. Additional factors like bone
morphogenic protein 2 (BMP-2) further stimulate osteogenic
differentiation of these cells [86]. Upon successful differentia-
tion, the ADSCs exposed to these factors in culture will pro-
duce osteoblastic genes and proteins such as alkaline
phosphatase, osteonectin, BMP-2, osteopontin, BMP-4, type
1 collagen, and Runx2 [87–89]. The successful osteogenic pro-
duction from ADSCs indicates that these cells are capable of
migration, proliferation, and differentiation should in vivo
transplantation take place, therefore, promising the regenera-
tion of the targeted bone tissue [90–92]. However, consistent
success in all studies with the ADSC potential to differentiate
into osteogenic lineages and proliferate still requires further
investigation both in vitro and in vivo [93].
2.8.1. Biological Differentiation. A biological growth factor is
a material that naturally occurs and is able to promote the
proliferation and differentiation of a particular, desired cell
type. In order for ADSC to differentiate into osteogenic cell
lines, various biological growth factors such as insulin-like
growth factor-1 (IGF-1), BMP-2, Wnt, basic fibroblast
growth factor (bFGF), ascorbic acid, and 1,25 vitamin D3
[94] are added for the acceleration of proliferation, differen-
tiation, and regulation of osteoblast cells as seen in Table 1:
TGF-β1, insulin, transferrin, dexamethasone, and ascorbic
acid for chondrogenic differentiation; insulin, transferrin,
and selenium for skeletal myogenic differentiation; and dexa-
methasone, ascorbic acid, and β-glycerophosphate for osteo-
genic differentiation. Therefore, the same MSC population in
the mesoderm exposed to different extrinsic stimuli can initi-
ate differentiation towards a specific cell type by triggering a
tissue-specific transcription factor, such as SOX5/6/9 for
chondrocytes and Runx2/Osterix for osteoblasts [95]. Signif-
icantly, some growth factors desirably inhibit the differentia-
tion of ADSCs [96] such as epidermal growth factor (EFG)
[97], platelet-derived growth factor (PDGF) [98], and vascu-
lar endothelial growth factor (VEGF) [99].
2.8.2. Chemical Differentiation. Chemical growth factors are
used in addition to biological growth factors due to their reg-
ulatory capacity to ensure the expected fate of MSC differen-
tiation [108]. Often, factors such as dexamethasone, calcium
phosphate families, hypoxia-inducible factor, and beta-
glycerol phosphate (see Table 2) are added for osteogenic dif-
ferentiation purposes and to prevent adipogenesis from tak-
ing place instead [85].
Although it has been established that certain growth fac-
tors, biological or chemical, have the potential to induce dif-
ferentiation of ADSCs into osteoblast-like cells, it has also
been noted that the control of osteogenesis and adipogenesis
in ADSCs is closely related. ADSCs have a preferential com-
mitment to adipogenic lineages unless specifically controlled
[112]. This concern for control of lineage-specific differenti-
ation using a combination of growth factors has prompted
the use of combining mechanical stimulation for differentia-
tion of ADSCs into osteoblasts. One such method is the use
of PBM, where numerous studies, using either PBM therapy
or in combination with biomaterials [113], have significantly
sped up the synthesis of the bone matrix by increasing vascu-
larization and decreasing inflammatory responses [114],
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which raises the osteocyte populations as well as bFGF [115]
along with promoting proliferation of cells [116].
2.8.3. Biophysical Differentiation. Within the SC microenvi-
ronment, MSCs are exposed to an assortment of biophysical
cues. For example, hydrostatic pressure, fluid flow and
accompanying shear stress, substrate strain and stiffness,
substrate topography, and electromagnetic fields are all bio-
physical indicators responsible for cell membrane morphol-
ogy changes and cell-matrix contacts and intracellular
junction force generation producing intracellular stress
[117]. The significance of biophysical prompts is identified
to stimulate gene expression changes bringing about SC dif-
ferentiation as identified with in vitro osteoblastic differenti-
ation amongst BMSCs [118]. However, a recent study
identified ADSCs for the purpose of osteogenic differentia-
tion in the presence of prefabricated scaffolds, as a more fea-
sible cell source than BMSCs and produced a successful bone
regenerative outcome [119]. Studies have identified the use of
mechanical stimulants like PBM to facilitate the proliferation
and differentiation of various cell lines [120], and therefore,
these might be a viable biophysical differentiation source to
use for ADSC differentiation into osteogenic lineages.
2.9. Photobiomodulation. When light is used through coher-
ent or incoherent light sources in a visible and near-infrared
(NIR) range, this is termed as PBM which stimulates endog-
enous chromophores bringing about both photochemical
and photophysical reactions [120, 121]. Even though the pro-
cess is still not fully comprehended, it is understood that cell
signalling cascades, as well as effector molecules, are stimu-
lated, promoting cell performance alterations [120, 122]. A
commonly proposed biochemical reaction of PBM using
wavelengths between 600 and 1100 nm is the “Cytochrome
c Oxidase (CCO) Theory.” This theorem is based on the pen-
etration of red or NIR light through a cell’s membrane, tar-
geting its mitochondria and initiating light absorption by
cytochrome c located within the mitochondria [123]. This
enzymatic chromophore then aids in the electron transport
chain during ATP production. An increase in ATP amounts
tends to induce an increase in gene transcription within the
cell nucleus bringing about an increase in DNA and RNA
synthesis initiating cell proliferation [124]. .Currently, an
ideal method to successfully increase proliferation and facili-
tate differentiation of stem cells through PBM is still being
explored for clinical use [116, 125, 126]. The cellular mecha-
nism variations caused by photochemical procedures, depen-
dency of dose [127], cell line limitations for dosage [128], and
the number of times as well as the period between each expo-
sure [129] remain under investigation for the establishment
of PBM parameters. However, the consensus amongst
research is that PBM stimulates proliferation of cells when
Table 1: Biological growth factors introduced to ADSCs for osteogenic differentiation.
Biological growth
factors
Outcome of growth factors Refs
Insulin-like growth
factor 1/2
Stimulate both proliferation and terminal differentiation of MSCs, fine-tuning transcription factor
expression levels and activity, and defining commitment towards specific lineages from the three germ




IGF-1 expression in MSCs enhances their proliferation with lower apoptosis; overexpression of IGF-1 in
osteoblasts can accelerate the rate of bone formation and increase the pace of matrix mineralization, IGF-
1-transfected human MSCs were able to upregulate expression of various osteoblast genes. 100 ng/mL of
IGF-1 promotes differentiation into osteoblast-like cells.
[101–
104]
IGF-2 IGF-2 appears to be more prominent than IGF-1 in promoting MSC self-renewal. [100]
BMP-2 Accelerates proliferation and differentiation of osteoblast cells. [105]
Wnt3a
Increased cell numbers and expanded the pool of MSCs capable of colony-forming unit- (CFU-) fibroblast
(CFU-F) and CFU- osteoblast (CFU-O); regulates osteoblast differentiation and maturation.
[106]
Wnt5a Maintained cell numbers and CFU-F and CFU-O numbers and increased the number of CFU-O. [106]
bFGF
bFGF was shown to be required in maintaining stemness and proliferation.
Enhances the development of osteogenic cells.
[94,
107]





Proliferates differentiated osteoblasts and inhibits ADSC differentiation.
[96–
99]
Table 2: Chemical growth factors introduced to ADSCs for osteogenic differentiation.
Chemical growth factors Outcome of growth factors Refs
Dexamethasone Proliferates differentiated osteoblasts and inhibits ADSC differentiation. [85, 108, 109]
Calcium phosphate Promotes the differentiation of osteogenic cell lines. [110]
Hypoxia-inducible factor Regulates osteogenesis. [111]
Beta-glycerol phosphate Proliferates differentiated osteoblasts and inhibits ADSC differentiation. [85, 108, 109]
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using a wavelength of/between 660 and 850nm and fluence
of/between 5 and 10 J/cm2 [130]. Additionally, green light
PBM ranging from 495nm to 570nm has been identified to
better improve cell differentiation; however, the biochemical
mechanism of this wavelength and further successful differ-
entiation ability remain under investigation [116, 125, 126].
Notably, green light is anticipated to increase intracellular
ROS in succinct amounts during the use of a low fluency
which has demonstrated enhanced involvement in cell differ-
entiation [125]. However, studies which used high fluences,
greater than 10 J/cm2, identified a biphasic dose response
which expressed significantly increased ROS levels, cell dam-
age, and cell death [131].
2.10. Effects of PBM on ADSCs. According to treatment
responses, ADSCs when irradiated at a wavelength of
825nm with fluences ranging between 5 and 15 J/cm2 are
stimulated but will often be inhibited by the use of a higher
fluence of 20 J/cm2 [132]. A study using a low-power laser
with the parameters of 660 nm ± 20 nm, 6 J/cm2, and
10mV/cm2 on ADSCs increases angiogenic factors and
decreases apoptosis occurrence [133]. Another study using
a low-power laser with the parameters of a wavelength of
660 nm + 20 nm, 220V + 22V, and 50Hz regulates the adhe-
sion of cells and their migration signals by increasing EKK1/2
and FAK thus increasing overall cell migration. An increase
in the proliferation, viability, and growth factors, particularly
hepatocyte growth factor (HGF) and PDGF, was demon-
strated in this study [134]. A study that used a low-power
laser of 808nm, 3 J/cm2, and 0.2W/cm2 showed both an
increase in cell proliferation and viability [135]. Significantly,
a low-power laser of 660nm and 0.5 and 1 J/cm2 with dose
dependency affects ADSCs and BMDMSCs by increasing
both cellular growth and proliferation without making
nuclear modifications and secretes growth factors VEGF,
HGF, and FGF [136]. The studies of significantly producible
results have been summarized in Table 3.
2.11. Combined Effects of PBM and Differentiation Inducers
on ADSCs. The combination of PBM, specifically green light,
red light, and NIR wavelengths, with the addition of multiple
growth factors, is believed to facilitate both cellular activity
regulation and the differentiation of ADSCs [140]. The poten-
tial stimulation and inhibition consequences of PBM have on
ADSCs tend to be wavelength and fluency factor dependent
[120]. There have been numerous studies performed using
various PBM parameters in combination with ADSC differen-
tiation inducers such as dexamethasone, ascorbic acid, beta-
glycerophosphate, L-glutamine, and ascorbate-2-phosphate;
a few examples of these studies are as follows (see Table 4).
A study differentiating ADSCs into osteoblasts using various
wavelengths but the same 3 J/cm2 dose five times every second
day established osteoblast differentiation stimulation to be
successful with 420nm and 540nm wavelengths [125].
Another study that used MSCs at a wavelength of 635nm
had no change in cell viability but a wavelength of 808nm
increased the deposits of calcium thus impacting osteogenic
differentiation [141]. The differentiation of ADSCs into osteo-
genic cell lines was also seen to be enhanced by the use of NIR
laser light [142]. Another report stated that ADSCs were pro-
liferated and differentiated by PBM at a red of 660nm and a
NIR of 810nm wavelengths and it is understood that mito-
chondrial activity as well as the production of ATP is stimu-
lated by PBM at this particular NIR wavelength [143].
Despite the majority of studies displaying positive photobios-
timulatory outcomes when regenerating bone using low-level
laser therapy, standardized parameters are yet to be estab-
lished for reproducible results [130].
2.12. Current and Future Challenges. The current rise in
global concern for osteoporosis as well as the risky, long-
term treatment solutions for this disease has sparked the
search and development of an efficient and minimally harm-
ful long-term treatment [144]. The promising branch of
regenerative medicine, SC therapy, is the emerging, probable
solution to this increasing concern [53]. The principle of
regenerative medicine is based on the healing of injured tis-
sue via cell usage and combinations of various biological
and/or chemical growth factors to restore cell structure, cell
functionality, and create newly formed repaired tissues
[145]. SC therapy is the rising star of regenerative medicine
as SCs are uniquely able to infinitely self-renew and possess
a multipotent ability into ESCs, iPSCs, TSPSCs, UCSCs, or
MSCs cell types, where each cell type provides its own










660 30 0.2 1.07 The viability of cells was increased. [137]
650 523 2, 4, 8 6.67 The 4 J/cm2 enhanced ADSC proliferation. [138]
680 3 and 4.5 — — Migration was sped up. [134]
808 200 3 0.2 Proliferation was sped up. [135]
636 85 5 9.3 Both the cell viability and proliferation were increased. [139]
825 — 5, 10, 15, 20 —
ADSC biphasic dose response occurred with fluences 15 and
20 J/cm2.
[132]
660 ± 20 — 6 10 An increase in angiogenic factors and decreased apoptosis. [133]
660 30 0.5, 1.0 —
Increased cellular growth and proliferation as well as VEGF, HGF,
and FGF growth factor secretion.
[136]
7Stem Cells International
benefits and limitations [66]. ADSCs are obtained from a
minimally invasive harvest and hold a large cell yield [5,
78]. The nonethically conflicting ADSCs significantly possess
the ability to differentiate into adipocyte, osteoblast, and
chondrocyte cell lineages [39]. According to studies, the dif-
ferentiation of ADSCs into a specific cell lineage requires the
influence of various growth factor combinations [146]. Suc-
cessful in vitro ADSC differentiation into an osteogenic cell
lineage has been accomplished by the unaccompanied use
of PBM using biological and/or chemical growth factors such
as ascorbic acid, β-glycerol phosphate, dexamethasone, 1,25
vitamin D3 [85], and BMP-2 [86] supplemented in an induc-
tion medium. The use of a specific concentration as well as
the combination of these growth factors varies amongst stud-
ies and requires optimization for result reproducibility pur-
poses along with functionality testing, as ADSCs have a
tendency of favouring differentiation into adipogenic cell lin-
eages unless purposely influenced into a different cell line
[112]. PBM alone is understood to only be involved in bio-
stimulation where an increase in cell proliferation and viabil-
ity is noted when using red or NIR light [147]. Green PBM
also has a biostimulatory effect causing an increase in intra-
cellular ROS [125] aiding in the preparation of ADSC differ-
entiation. However, it can therefore be said that the
combined use of transducers and PBM on ADSCs for differ-
entiating into osteogenic cell lineages could be a more effec-
tive technique than using these factors alone, where in vitro
optimization and successful differentiation of ADSCs can
be then studied in vivo. According to studies above, PBM at
wavelengths ranging from 660nm to 850nm and fluences
ranging between 5 and 15 J/cm2 have facilitated ADSC differ-
entiation into a desired cell lineage and enhanced prolifera-
tion [142]. Ideal ADSC differentiation into osteogenic cell
lineage occurrence may be deduced from the above at wave-
lengths of either red light, green light, or NIR at a fluence
below 15 J/cm2. The use of green light wavelengths has been
recognized to stimulate calcium ion channel exchange that
leads to the increased expression of intracellular ROS in
physiologically viable amounts which is understood to
enhance cell differentiation [125]. The use of red light or
NIR wavelengths has displayed efficient cytochrome c absor-
bance which enhances cell proliferation as well as cell viabil-
ity and, when in the presence of differentiation transducers,
facilitates the differentiation of cells [110, 126]. A fluency that
is greater than 10 J/cm2 initiates biphasic dosing and ulti-
mately causes cell death [131]; thus, fluences below 10 J/cm2
are favorable. A power output below 100mW will exclude
the thermal effect [148] that can be introduced with light
exposure omitting this external factor that might influence
the cells negatively. The usage of these parameters will be best
fitting for combining PBM with the use of differentiation
growth factors to effectively enhance the differentiation of
ADSCs into osteogenic cell lineages. The parameters of
PBM such as the wavelength of the laser, the energy fluence,
the number of times of exposure, and the period between
each exposure [120] remain under current in vitro investiga-
tion for the establishment of optimal PBM parameters and a
fixed protocol. The development of a fixed in vitro protocol
for the use of ADSC differentiation into osteoblasts will pro-
duce a safe and sound procedure that may be efficiently
translated in vivo for the clinical use of osteoporotic treat-
ment and as a regenerative tool [130].
3. Conclusion
In conclusion, the use of various biological and chemical
growth factors, in combination with a physical inducer, par-
ticularly PBM successfully proliferates and differentiates
ADSCs into osteoblast cells. However, this procedure awaits
the establishment of an ideal, set protocol of assured growth
factors and PBM parameters as there are various published
papers debating factors such as growth factors, wavelengths,
and fluencies. The established protocol would ensure consec-
utive successful proliferation and differentiation for the spe-
cific ADSC cell lines into osteoblasts. Despite these
inconsistencies, the use of PBM especially on this cell line
for osteoblastic differentiation has been remarkable and
remains promising to move forward in methodology, to
achieve success in vitro, and possibly to achieve clinical stud-
ies as a possible form of treatment for osteoporosis.
Data Availability
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Dexamethasone, ascorbic acid, beta-
glycerophosphate
420, 540 3
Increased the concentration of intracellular calcium thus
increased osteogenic relative gene expression.
[125]
Dexamethasone, ascorbic acid, beta-
glycerophosphate, L-glutamine
635, 808 0.4
Increased the focal adhesion-localized vinculin which
promotes osteogenic differentiation.




809 0.5, 1, 2 Mineralization occurred which indicated cell differentiation. [142]
Dexamethasone, ascorbic acid, beta-
glycerophosphate
810, 980 3, 0.3 Osteogenic-related gene expression was upregulated. [143]
8 Stem Cells International
which have been cited. These prior studies (and datasets) are
cited at relevant places within the text as references.
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